Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Chromatin immunoprecipitation (ChIP) Sequencing Market from 2024 to 2025?

In recent years, the market size for chromatin immunoprecipitation (ChIP) sequencing has seen substantial growth. It’s expected to rise from $13.89 billion in 2024 to $15.6 billion in 2025, with a compound annual growth rate (CAGR) of 12.3%. Factors contributing to the growth during the historical period include advancements in gene regulation understanding, increased studies in epigenetics, development of data analysis and bioinformatics tools, along with cost reduction and scalability.

What Is the Projected Market Size of the Chromatin immunoprecipitation (ChIP) Sequencing Market?

Expectations are high for the chromatin immunoprecipitation (ChIP) sequencing market size to experience speedy expansion in the upcoming years. It is projected to rise to $25.37 billion in 2029, with a compound annual growth rate (CAGR) of 12.9%. The anticipated growth during the forecast period can be credited to factors such as industry investments and competition, the application of ChIP in clinical settings and diagnostics, the need for biomarker discovery, rapid advancements in bioinformatics tools, and its broad usage in drug discovery. Key trends during the forecast period include its application in clinics and diagnostics, a focus on histone modifications, usage in new areas of research, improvements in sample preparation, and the integration of multi-omics.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13265&type=smp

Who are the Major Competitors in the Chromatin immunoprecipitation (ChIP) Sequencing Market Outlook?

Major companies operating in the chromatin immunoprecipitation (chip) sequencing market report are F. Hoffmann La Roche Ltd., Merck KGaA, Thermo Fisher Scientific Inc., Becton Dickinson and Co., Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Bio-Techne Corp., BGI Genomics Co. Ltd., Promega Corporation, GenScript Biotech Corporation, Abcam PLC, BioLegend Inc., Hamilton Co., Takara Bio Inc., Novogene Co. Ltd., Oxford Nanopore Technologies PLC, Porvair Sciences Ltd., Creative Biolabs Inc., Cell Signaling Technology Inc., GENEWIZ Inc., Zymo Research Corporation, CD Genomics, Active Motif Inc., Psomagen Inc., EpiCypher Inc.

What Is Fueling Growth in the Chromatin immunoprecipitation (ChIP) Sequencing Market?

Rising incidences of prostate cancer are expected to spur the growth of the chromatin immunoprecipitation (ChIP) sequencing market. This type of cancer originates in the prostate gland, a small organ in men responsible for producing semen-enriching fluid. ChIP-seq plays an essential role in prostate cancer research by offering a detailed analysis of the molecular activities that instigate the disease, providing infectious data for scientists to develop more efficient and targeted treatments. For instance, the American Cancer Society reported in January 2023 that the US recorded 288,300 new prostate cancer cases and 34,700 subsequent deaths in 2023. This rise in prostate cancer prevalence marks a significant push factor for the chromatin immunoprecipitation (ChIP) sequencing market’s expansion. The expanding use of personalized medicine is another factor boosting the growth of the chromatin immunoprecipitation (ChIP) sequencing market. This modern healthcare approach customizes medicinal decisions, treatments, and interventions to match each patient’s unique features. To achieve this, personalized medicine often tags specific genetic markers related to particular diseases or disorders. As a valuable tool, ChIP sequencing maps out epigenetic adjustment, such as DNA methylation and histone alterations, thereby helping understand the genetic roots of diseases. For example, the Personalized Medicine Coalition confirmed in 2022, 37 groundbreaking molecular bodies were approved by the FDA’s Center for Drug Evaluation and Research, with 12 of the 35 therapeutic NMEs, representing roughly 34%, being specific drugs. Hence, the rising incorporation of personalized medicine is fuelling the growth of the chromatin immunoprecipitation (ChIP) sequencing market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13265&type=smp

Which Chromatin immunoprecipitation (ChIP) Sequencing Market Segments Are Growing the Fastest?

The chromatin immunoprecipitation (ChIP) sequencing market covered in this report is segmented –

1) By Type: DNase-Sequencing, FAIRE-Sequencing

2) By Technology: Targeted Sequencing And Re-Sequencing, Whole Genome Sequencing And Whole Exome Sequencing

3) By Workflow: Pre-Sequencing, Sequencing, Data Analysis

4) By Application: Consumables And Reagents, Service, Other Applications

5) By End-User: Academic Research Institutes, Clinical Research Institutes, Hospitals And Clinics, Pharmaceuticals And Biotechnology Companies, Other End Users

Subsegments:

1) By DNase-Sequencing: DNase I Hypersensitivity Mapping, DNase-Seq For Open Chromatin Regions

2) By FAIRE-Sequencing: Formaldehyde-Assisted Isolation Of Regulatory Elements (FAIRE), FAIRE-Seq For Active Regulatory Regions

Which Industry Trends Are Shaping the Future of the Chromatin immunoprecipitation (ChIP) Sequencing Market?

Key players in the chromatin immunoprecipitation (ChIP) sequencing market are harnessing novel technologies like hmqChIP-seq (high-throughput multiplex quantitative Chromatin Immunoprecipitation sequencing) to magnify the precision and capability of epigenomic research, thereby propelling progress in personalized medicine and drug discovery. hmqChIP-seq, a pioneering technology, is tailor-made to augment investigations into genetic modifications across the genome. For example, in June 2024, a technological company specializing in life sciences based in Sweden, Epigenica, launched its patented hmqChIP-seq technology integrated EpiFinder Platform. This ground-breaking platform allows for high-throughput, multiplex quantitative examinations crucial to epigenomic research, enabling the generation of 192 genome-wide profiles simultaneously from a maximum of 24 samples, thereby facilitating large-scale trials at unparalleled speed and cost-effectiveness.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/chromatin-immunoprecipitation-chip-sequencing-global-market-report

Which Countries Are Leading the Chromatin immunoprecipitation (ChIP) Sequencing Market?

North America was the largest region in the chromatin immunoprecipitation (ChIP) sequencing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chromatin immunoprecipitation (chip) sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13265

This Report Delivers Insight On:

1. How big is the chromatin immunoprecipitation (chip) sequencing market, and how is it changing globally?

2. Who are the major companies in the chromatin immunoprecipitation (chip) sequencing market, and how are they performing?

3. What are the key opportunities and risks in the chromatin immunoprecipitation (chip) sequencing market right now?

4. Which products or customer segments are growing the most in the chromatin immunoprecipitation (chip) sequencing market?

5. What factors are helping or slowing down the growth of the chromatin immunoprecipitation (chip) sequencing market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model